GeneDx Holdings Corp. Warrant (WGSWW) Stock Price

WGSWWStock

$0.00

Market Cap—

P/E—

PEG Ratio—

Div yield—

Beta1.97

WGSWW Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-107.33%

Price vs S&P 500 (4W)-97.35%

VGM Score2.14

Industry Peers — Health Services(21)

Symbol	Value Score	Growth Score	Momentum Score	P/E Ratio (Annual)	Revenue Growth TTM (YoY)	Operating Margin (TTM)	ROE (TTM)	Price
WGSWWGeneDx Holdings Corp. Warrant	—	—	F	—	—	—	—	$0.00
LFSTLifeStance Health Group, Inc. Common Stock	D	A	B	464.3x	61.1%	4.9%	3.4%	$11.74
PRVAPrivia Health Group, Inc. Common Stock	C	B	C	125.5x	24.1%	1.9%	3.8%	$22.52
WGSGeneDx Holdings Corp. Class A Common Stock	F	B	D	—	25.4%	-21.8%	-38.7%	$63.61
PNTGThe Pennant Group, Inc. Common Stock	D	B	B	49.4x	37.9%	5.7%	9.5%	$41.87
USPHUS Physical Therapy Inc	C	D	C	32.3x	11.3%	9.4%	6.8%	$85.71
INNVInnovAge Holding Corp. Common Stock	D	C	C	—	15.9%	0.3%	-1.1%	$8.85
OMDAOmada Health, Inc. Common Stock	D	B	D	—	8.3%	-0.8%	1.8%	$17.63
PIIIP3 Health Partners Inc. Common Stock	A	C	D	—	2.8%	-9.9%	10.3%	$4.14
SRTAStrata Critical Medical, Inc. Class A Common Stock	B	B	C	9.7x	18.8%	-8.0%	14.3%	$4.54
ALPSALPS Group Inc Ordinary Share	—	—	D	—	—	—	—	$0.34
EUDAEUDA Health Holdings Limited Ordinary Shares	C	B	C	—	66.9%	-36.5%	-1.8%	$15.40
DCGODocGo Inc. Common Stock	A	D	F	3.3x	-32.4%	-62.3%	-115.6%	$0.27
ATPCAgape ATP Corporation Common Stock	B	F	F	—	-26.9%	-295.9%	-5.1%	$1.57
VSEEVSee Health, Inc. Common Stock	A	D	F	—	—	-77.4%	-177.5%	$2.10
EUDAWEUDA Health Holdings Limited Warrant	—	—	C	—	—	—	—	$0.03
EVSDEaton Vance Short Duration Income ETF	—	—	C	—	—	—	—	$50.04
PIIIWP3 Health Partners Inc. Warrant	—	—	D	—	—	—	—	$0.01
SRTAWStrata Critical Medical, Inc. Warrants	—	—	F	—	—	—	—	$0.00
TALKTalkspace, Inc. Common Stock	F	B	B	111.7x	22.6%	-1.2%	1.0%	$0.00
TALKWTalkspace, Inc. Warrant	—	—	F	—	—	—	—	$0.00
VSEEWVSee Health, Inc. Warrant	—	—	D	—	—	—	—	$0.02

About GeneDx Holdings Corp. Warrant

GeneDx Holdings is a genomics company providing diagnostic testing for rare and ultra-rare pediatric genetic disorders through exome and genome sequencing. The company is positioned to capitalize on the expected shift toward genetic testing as a standard diagnostic tool for genetic disease. Its services enable early diagnosis and precision medicine while generating valuable genomic data for clinical discovery and improved patient outcomes.